Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...

Triple-negative breast cancer is a fast-moving form of breast cancer that’s more common in younger women and harder to treat ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...

Inluriyo is approved for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after prior endocrine therapy failure. The EMBER-3 trial showed Inluriyo reduced cancer progression or death ...

Strickland survived a lesser-known, aggressive form of breast cancer, and is now using her second chance on life to be an ...

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early ...